These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36739511)

  • 1. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
    Lipton RB; Blumenfeld A; Jensen CM; Croop R; Thiry A; L'Italien G; Morris BA; Coric V; Goadsby PJ
    Cephalalgia; 2023 Feb; 43(2):3331024221141686. PubMed ID: 36739511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
    Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
    Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
    Yu S; Guo A; Wang Z; Liu J; Tan G; Yang Q; Zhang M; Yibulaiyin H; Chen H; Zhang Y; Croop R; Sun Y; Liu Y; Zhao Q; Lu Z
    J Headache Pain; 2024 Apr; 25(1):57. PubMed ID: 38627638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
    Lipton RB; Singh RBH; Revicki DA; Zhao S; Shewale AR; Lateiner JE; Dodick DW
    J Headache Pain; 2022 Apr; 23(1):50. PubMed ID: 35468729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
    Johnston K; Powell LC; Popoff E; L'Italien GJ; Pawinski R; Ahern A; Large S; Tran T; Jenkins A
    J Med Econ; 2024; 27(1):627-643. PubMed ID: 38590236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lipton RB; Thiry A; Morris BA; Croop R
    J Pain Res; 2024; 17():2431-2441. PubMed ID: 39070853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
    N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
    Yu S; Kim BK; Guo A; Kim MH; Zhang M; Wang Z; Liu J; Moon HS; Tan G; Yang Q; McGrath D; Hanna M; Stock DA; Gao Y; Croop R; Lu Z
    Lancet Neurol; 2023 Jun; 22(6):476-484. PubMed ID: 37210098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review.
    DeFalco AP; Lazim R; Cope NE
    Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
    Lipton RB; Schmidt P; Diener HC
    Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
    Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
    J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry.
    Ruscheweyh R; Gossrau G; Dresler T; Freilinger T; Förderreuther S; Gaul C; Kraya T; Neeb L; Ruschil V; Straube A; Scheidt J; Jürgens TP
    J Headache Pain; 2023 Oct; 24(1):135. PubMed ID: 37817093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review.
    Leroux E; Buchanan A; Lombard L; Loo LS; Bridge D; Rousseau B; Hopwood N; Matthews BR; Reuter U
    Adv Ther; 2020 Dec; 37(12):4765-4796. PubMed ID: 32990921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
    Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
    Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
    Yang CP; Liang CS; Chang CM; Yang CC; Shih PH; Yau YC; Tang KT; Wang SJ
    JAMA Netw Open; 2021 Oct; 4(10):e2128544. PubMed ID: 34633423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
    Joyner KR; Morgan KW
    Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.